The Biomarkers of Venous Thromboembolism in Cancer Patients

Soraya Mezouar (1, 2) , Roxanne Darbousset (2, 1) , Corinne Frere (2, 1) , Philippe Debourdeau (3) , Dominique Farge-Bancel (3) , Francoise Dignat-George (4, 2, 1) , Laurence Panicot-Dubois (2, 1) , Christophe Dubois (2, 1)

1 Physiopathologie de l'Endothelium
2 VRCM - Vascular research center of Marseille
3 Dep Oncol - AVIGNON - Département d'Oncologie
4 LA CONCEPTION - Hôpital de la Conception [CHU - APHM]

Today, the thrombosis associated with cancer is clearly established. The risk of venous thromboembolism (VTE) in cancer is dependent on clinical parameters of cancer patients and the type of tumor. Thus, the relationship between VTE and the type of cancer is complex, caused by the tumor progression, the inflammatory state, and the hemostasis. Several biomarkers had been identified to detect VTE in cancer patients. This review summarizes usual biomarkers, assessed regularly in laboratory and included in risk assessment score, and discusses new biomarkers for prediction of VTE.

Keywords: Thrombosis; Cancer; Biomarkers; TISSUE FACTOR ACTIVITY; PANCREATIC-CANCER; P-SELECTIN; IN-VIVO; THROMBOSIS; MICROPARTICLES; COAGULATION; METASTASIS; PREDICTION; RISK

Domains: Life Sciences [q-bio]

Soraya Mezouar, Roxanne Darbousset, Corinne Frere, Philippe Debourdeau, Dominique Farge-Bancel, et al.. The Biomarkers of Venous Thromboembolism in Cancer Patients. Oncologie, 2016, 18 (1), pp.17-21. ⟨10.1007/s10269-015-2579-z⟩. ⟨hal-01453350⟩